<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1484">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141838</url>
  </required_header>
  <id_info>
    <org_study_id>307308294</org_study_id>
    <nct_id>NCT05141838</nct_id>
  </id_info>
  <brief_title>Vitamin D Status and Bone Metabolism Status in Children With Congenital Epidermolysis Bullosa</brief_title>
  <official_title>Vitamin D Status and Bone Metabolism Status in Children With Congenital Epidermolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Medical Research Center for Children's Health, Russian Federation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Medical Research Center for Children's Health, Russian Federation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective prospective study is aimed at studying the level of vitamin D supply and&#xD;
      identifying markers of bone tissue remodeling in order to develop approaches to the&#xD;
      prevention of osteopenia and osteoporosis in children with congenital epidermolysis bullosa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This retrospective prospective interventional study will examine vitamin D availability and&#xD;
      its relationship with clinical disease, patient gender and age, and season. The mechanisms of&#xD;
      impairment of phosphorus-calcium metabolism and bone tissue metabolism will be analyzed on&#xD;
      the basis of biochemical parameters and instrumental research methods in children with&#xD;
      dystrophic EBE in order to develop personalized approaches for correcting vitamin D status&#xD;
      and bone metabolism disorders in children with EBE, followed by an assessment of their&#xD;
      clinical efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin D level</measure>
    <time_frame>From Baseline up to 24 weeks</time_frame>
    <description>Study of the provision of vitamin D in children with dystrophic and simple forms of EBE based on the level of 25 (OH) vitamin D (25 hydroxycholecalciferol) in the blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phosphorus-calcium metabolism assessment</measure>
    <time_frame>From Baseline up to 24 weeks</time_frame>
    <description>Study of levels of calcium, phosphorus, parathyroid hormone, creatinine, magnesium, albumin in the blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the state of bone tissue</measure>
    <time_frame>From Baseline up to 24 weeks</time_frame>
    <description>Study of levels of alkaline phosphatase, osteocalcin, b-CrossLaps, P1NP in the blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of indicators of physical development</measure>
    <time_frame>From Baseline up to 24 weeks</time_frame>
    <description>Z-score calculation (weight-for-height z-score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of bone mineral density</measure>
    <time_frame>From Baseline up to 24 weeks</time_frame>
    <description>dual-energy X-ray densitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone age assessment</measure>
    <time_frame>From Baseline up to 24 weeks</time_frame>
    <description>X-ray of the bones of the hand with an assessment of bone age</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Bullosa Epidermolysis</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Osteoporosis</condition>
  <condition>Osteopenia</condition>
  <condition>Phosphorus and Calcium Disorders</condition>
  <arm_group>
    <arm_group_label>Group 1 - Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving vitamin D supplements in therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Oral nutrional supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving oral nutrional supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - Vitamin D+Oral nutrional supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving vitamin D supplements and oral nutrional supplement in therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with dystrophic form of congenital epidermolysis bullosa who have not taken vitamin D supplements and/or oral nutrional supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Adding vitamin D preparations to the therapy in the individual required dosage to correct the deficient state</description>
    <arm_group_label>Group 1 - Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral nutrional supplement</intervention_name>
    <description>Adding оral nutrional supplement to the therapy depending on the degree of protein-energy malnutrition</description>
    <arm_group_label>Group 2 - Oral nutrional supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Vitamin D+Oral nutrional supplement</intervention_name>
    <description>Adding both (vitamin D preparations and оral nutrional supplement) to the therapy in children with dystrophic form of congenital epidermolysis bullosa, suffering from protein-energy malnutrition and vitamin D deficiency</description>
    <arm_group_label>Group 3 - Vitamin D+Oral nutrional supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Verified diagnosis of EB;&#xD;
&#xD;
          -  Signing by parents (legal representatives) of informed consent to participate in the&#xD;
             study and fulfill the requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  not planned&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Medical Research Center for Children's Health</name>
      <address>
        <city>Moscow</city>
        <zip>119296</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Yu. Pronina</last_name>
      <phone>+7(916)934-40-81</phone>
      <email>krapchatovaiv@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children, Only</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

